A u t o m a t i c a ll y g e n e r a t e d r o u g hP D F b y P r oo f C h e c k f r o m R i v e r V a ll e y T e c h n o l o g i e s L t d DE GRUYTER EntrepreneurshipResearchJournal . 2018 ; 20170159 Hyunsung D Kang 1 A Start - Up ‚Äô s R & D Stages and the Evolution of Financing Sources : Evidence from the Biotechnology Industry 1 Campbell School of Business , Berry College , 2277 Martha Berry Hwy NW , Mount Berry , USA , E - mail : hkang @ berry . edu . http : / / orcid . org / 0000 - 0001 - 6309 - 0857 . Abstract : The co - existence of angel , independent venture capital ( IVC ) , and corporate venture capital ( CVC ) in the en - trepreneurial finance market raises a natural question of why a start - up finances its projects from one source over another . This question becomes more complicated to address because a start - up grows or declines dynam - ically . Using a life cycle theory of entrepreneurial finance , which suggests that a start - up uses several financing sources as it reaches certain thresholds in its life cycle accordingly , I explore this selection issue with my dataset on 113 biopharmaceutical start - ups . I find that these start - ups tend to finance their projects mostly from solely IVCs or CVCs rather than angels and syndicated investors combining IVCs and CVCs when they have more preclinical and phase I products in their R & D pipelines ; and from CVCs or syndicated investors rather than angels and IVCs when they do more phase II and phase III products . Keywords : venture capital , corporate venture capital , angel , entrepreneurial finance , biopharmaceutical industry JEL classification : G34 , L24 , L65 , O32 DOI : 10 . 1515 / erj - 2017 - 0159 1 Introduction Similar to other high - technology start - ups , start - ups based on genetic engineering technology , which have driven new drug development processes , often experience a ‚Äú valley of death ‚Äù transitional phase where de - veloping technology is deemed promising yet without validated commercial potential and , therefore , fails to attract capital necessary for continued development ( National Research Council 2009 ) . This gap in the early stages of product development has grown due to several factors , including increasing regulatory burdens , concerns about coverage and payment for new medical innovations , and uncertainties related to intellectual property policies ( Pharma 2015 ) . As a result , these start - ups heavily rely on several forms of private capital for financing , including independent venture capital firms ( IVCs ) , corporate venture arms of established corpo - rations ( CVCs ) , and business angels . 1 Given the high cost of drug development ( e . g . , on average $ 1 . 0 billion in 1990s and $ 2 . 6 billion in 2000s ) , it is extremely rare to observe a start - up that is able to grow and survive without funding from these sources . The co - existence of several forms of entrepreneurial financing sources raises interesting questions of why a start - up finances its projects from one over another ; and more importantly , how this choice evolves as it grows . A growing body of literature has suggested that each entrepreneurial financing source has its own motives and investment patterns as well as a range of services they provide to start - ups ( see Figure 1 ) . These questions , however , remains not fully answered because start - ups dynamically face several unique options for funding in their life cycles within a comprehensive set of investor groups . For example , a strand of literature has recently focused on a comparison of IVCs and CVCs ( B vs . C in Figure 1 ) . However , we know little about how a start - up particularly evolves in choosing a certain type of investors in its life span and how other types of investor groups , including angels and syndicated investors combining IVCs and CVCs , are involved with these dynamic financing decisions . Apparently , these issues are involved with a start - up ‚Äô s growth strategy and outcomes . As a result , these questions should be examined within a comprehensive picture of entrepreneurial financing sources in a dynamic manner . In a broad sense , these issues help us understand why several types of investors co - exist in the entrepreneurial finance market . HyunsungDKang isthecorrespondingauthor . ¬©2018WalterdeGruyterGmbH , Berlin / Boston . 1 A u t o m a t i c a ll y g e n e r a t e d r o u g hP D F b y P r oo f C h e c k f r o m R i v e r V a ll e y T e c h n o l o g i e s L t d Kang DEGRUYTER Figure 1 : Entrepreneurial financing sources and map to prior literature . Conditional on entering the direct financing market , a start - up can make a series of financing choices among four representative entrepreneurial financing sources , including business angels , IVCs , CVCs , and syndicated investments combining IVCs and CVCs . I map the current liter - ature by these financing sources in this figure . The branches , including A , B , C , and D , represent financing sources . For example , the Dushnitsky and Shapira ( 2010 ) paper is mapped to B vs . C . That is , the paper finds a performance gap be - tween IVCs and CVCs , and this performance gap is sensitive to CVCs ‚Äô compensation scheme . My study is the first , to my knowledge , to holistically consider the linkages between a start - up ‚Äô s product development stages within its R & D pipeline and four entrepreneurial financing sources . It is also the first paper to demonstrate the importance of a start - up ‚Äô s product development stages in a context where a start - up evolves to choose financing sources . To address these issues , I elaborated on two research streams . The first is the literature on the entrepreneurial finance market ( see several issues in the market , including alternative sources of capital , financial contracting issues , public policy , and the dynamics of private equity returns in Denis ( 2004 ) ) . The central idea of this liter - ature is that each type of investors has its own investment motives and arrangements . A prominent example is offered by the literature on CVC activities , which claims that , unlike IVCs , CVCs can provide not only financial capital but also quick access to markets , technological assistance , and product recognition through marketing , distribution , and research support for start - ups ( Park and Steensma 2011 ; Bertoni , Colombo , and Grilli 2013 ) . This unique attribute of CVC may attract start - ups in several ways that IVCs may not be able to emulate . In contrast , the interests of CVCs and start - ups may be more misaligned when compared to those of IVCs and start - ups due to the desire of CVCs to use the start - ups ‚Äô resources for their own sakes ( Hellmann 2002 ; Katila , Rosenberger , and Eisenhardt 2008 ; Dushnitsky and Shaver 2009 ; Maula , Autio , and Murray 2009 ; Pahnke , Katila , and Eisenhardt 2015 ) . Furthermore , business angels may differ IVCs and CVCs in several ways . First , angel investors are recognized to be more readily available relative to CVCs and IVCs ( Gompers 1995 ; Kaplan and Str√∂mberg 2001 ; Wong , Bhatia , and Freeman 2009 ) . Second , IVCs and CVCs often add value to start - ups by exerting complementary assets and increase the chance of R & D success . However , angels generally do not have such complementary assets ( Chemmanur and Chen 2014 ) and the amount of individual investment is often smaller than that of IVCs and CVCs . Some angels take advantages for start - ups over other investors by making their investment decisions through a well - documented process and , in some cases , formal votes ( Kerr , Lerner , and Schoar 2014 ; Puri and Zarutskie 2012 ) . In addition , the unique investment patterns and benefits of syndicated investors combining both IVCs and CVCs simultaneously have been intensively discussed in the existing literature ( Bygrave 1987 ; Dushnitsky and Shapira 2010 ; Lerner 1994a ; 1994b ) . Figure 1 illustrates these four entrepreneurial financing sources and maps to prior literature . The second research stream I considered is the literature on a life cycle theory of entrepreneurial finance ( Puri and Zarutskie 2012 ; Hellmann and Thiele 2015 ; Dutta and Folta 2016 ) . This perspective has focused on a central question of what extant early - stage financiers have a substantial impact on the start - ups in which they have invested . This strand of literature suggests that the combination of intensive monitoring , provision of value - added services , and powerful control rights leads to improved governance and operations in portfolio firms , lower capital constraints , and ultimately stronger firm growth and performance ( Kerr , Lerner , and Schoar 2014 ) . Particularly , this literature has examined on how this active role of investors can be characterized in the early part of start - ups ‚Äô life cycles and the eventual differences in outcomes ( Schwienbacher 2013 ; Vanacker , Meuleman , and Manigart 2014 ; Dutta and Folta 2016 ) . The empirical documentation of this impact along with start - ups ‚Äô life cycles ‚Äì from birth to death ‚Äì has been challenging due to the lack of available data and theoretical guidance . This study uses a setting from the biopharmaceutical industry where collaborative relationships between ge - netic engineering based start - ups and their investors are common . There are several reasons that facilitate these collaborative relationships . These reasons include addressing the most complex scientific challenges , overcom - ing regulatory hurdles , and avoiding the high uncertainty of reimbursement of sunk cost . As a result , start - ups seek the necessary capital and complementary assets to exploit their growth opportunities , whereas investors look for investment opportunities to utilize their resources and enhance the rates of return , which are not always necessarily capital gains . Moreover , biopharmaceutical start - ups have common and distinguishable product de - 2 A u t o m a t i c a ll y g e n e r a t e d r o u g hP D F b y P r oo f C h e c k f r o m R i v e r V a ll e y T e c h n o l o g i e s L t d DEGRUYTER Kang velopment stages within their R & D pipelines , including preclinical , phase I , phase II , phase III , and launched stages . Given technology is often the most important resource for a start - up , the advancement of these stages become essential factors that match the start - up with potential investors . Since technology is multifaceted and heterogeneous by its nature , these stages can be a suitable index to suggest the comprehensive status of a start - up ‚Äô s focal technologies . The synthesis of the above frameworks and setting allows me to empirically analyze a start - up ‚Äô s selection on financing sources in a dynamic manner . Using a dataset on the funding activities of 113 biotechnology start - ups , I find that a start - up tends to finance its projects from CVCs , IVCs , angels , and syndicated investors combining CVCs and IVCs in order when it develops more preclinical products ; from IVCs , CVCs , angels , and syndicated investors when it does more phase I products ; from syndicated investors , CVCs , IVCs , and angels when it does more phase II products ; from syndicated investors , CVCs , angels , and IVCs when it does more phase III products . By attempting to address the dynamics of a start - up ‚Äô s financing sources , this study contributes to several strands of the literature . Firstly , this study provides a linkage between a start - up ‚Äô s life cycle theory and available financing options in the entrepreneurial finance market based on a dynamic perspective . In doing so , this study provides systematic evidence that suggests that a start - up strategically utilizes various financing sources to fulfill necessary resources as it reaches critical thresholds in its life cycle . This evidence is essential to formulate and expand the boundary of a life cycle theory of entrepreneurial finance that has been inexplicitly defined in the existing literature ( Puri and Zarutskie 2012 ; Hellmann and Thiele 2015 ; Dutta and Folta 2016 ) . Secondly , this study explicitly examines a comprehensive set of investor groups that include angels and syndicated investors along with CVCs and IVCs . As a result , this study , in a broader sense , contributes to spec - ify the objectives of entrepreneurial financing market where several types of investors co - exist simultaneously ( Lerner 1994a ; Chemmanur and Chen 2014 ; Dushnitsky and Shapira 2010 ) . Given my findings that support a life cycle theory of entrepreneurial finance , these several types of investors are complementors rather than substitutors by adding value to a start - up in a timely manner ( e . g . , a certain product development stage ) and thus their co - existence is justified . Furthermore , this study contributes to the literature on optimal corporate relations and financing arrange - ments for a start - up ( e . g . , Hellmann 2002 ; Katila , Rosenberger , and Eisenhardt 2008 ; Dushnitsky and Shaver 2009 ) . This line of studies has been focused on a potential tension between resource constraints and appropri - ation problems that may affect a start - up ‚Äô s decision regarding financing sources . In sum , my findings suggest that the status of a start - up ‚Äô s product development process plays a crucial role in accessing to several types of investors . This dynamic feature of my findings extends the prior literature that compares the advantages and disadvantages of each financing sources in a static manner . As a start - up matures , it responds technological and managerial changes and become an active decision maker to procure the necessary resources . 2 Theory and Hypotheses 2 . 1 Related Literature A start - up is often resource - constrained and needs to reach out beyond its boundary in order to procure crit - ical resources from the external environment ( Park and Steensma 2011 ; Bertoni , Colombo , and Grilli 2013 ) . To reduce uncertainty in obtaining needed resources , a start - up may restructure its dependency with a variety of tactics , including seeking alternative sources of supply , building inter - firm networks , and improving its position to absorb constraints ( Burt 1983 ; Casciaro and Piskorski 2005 ) . My theoretical framework assumes that a start - up chooses a certain type of investors exactly in this manner . An attempt to obtain external financing becomes increasingly successful as a start - up has more available options and a superior position in the entrepreneurial financing network surrounding it ( Lerner , Shane , and Tsai 2003 ) . Prior studies have suggested that each type of investors is important and differ from another in various con - texts ( see Figure 1 that maps prior studies ) . Business angels are often individual investors and finance smaller amounts than institutional investors , including IVCs and CVCs , generally do , but their total financing amount in the industry is larger than that of institutional investors ( Freear , Sohl , and Wetzel 1995 ) . Both angels and institutional investors may be able to add value to start - ups , yet the value of angels added for start - ups is still controversial in the literature . For example , on the contrary to the assumption regarding the incapability of an - gels to provide value - addition for start - ups ( e . g . , Chemmanur and Chen 2014 ) , Kerr , Lerner , and Schoar ( 2014 ) document that start - ups funded by prominent angel groups experience superior outcomes to their counter - parts in terms of survivals , exists , employment , patenting , Web traffic , and financing . Moreover , Dutta and Folta ( 2016 ) suggest that institutional investors and business angels contribute equally to the innovation rates 3 A u t o m a t i c a ll y g e n e r a t e d r o u g hP D F b y P r oo f C h e c k f r o m R i v e r V a ll e y T e c h n o l o g i e s L t d Kang DEGRUYTER of start - ups and these effects are non - additive . However , institutional investors backed start - ups have more impactful innovations and experience faster commercialization rates . CVCs and IVCs also significantly differ in several ways . Firstly , unlike IVCs that pursue mainly capital gains , CVCs often seek investment opportunities to redirect and guide their parent companies ‚Äô R & D activities using knowledge spillovers originating from start - ups . Apparently , IVCs want to maximize the rate of returns from their investments and this is exemplified by 20 . 7 % of net return to investors after fees and other costs between 1986 and 2008 ( Cambridgeassociates . com ) . In contrast , technology spillovers pursued by CVCs come from ex - posure and early access to the technologies and products being developed by portfolio firms , allowing the parent companies of CVCs to adjust their future R & D activities and strategic agendas ( Dushnitsky and Lenox 2005 ; Dushnitsky and Lenox 2006 ) . Secondly and by the nature of CVCs , CVCs have a relatively high possibility to misappropriate a start - up ‚Äô s technology for their own sakes , yet IVCs have a minimal risk of misappropriation ( Katila , Rosenberger , and Eisenhardt 2008 ; Dushnitsky and Shaver 2009 ) . There is a potential tension formed between start - ups ‚Äô resource needs and appropriation concerns . Start - ups are pushed toward raising funds for their projects from CVCs due to their dependence on CVCs for needed resources ; and they are also pushed away from CVCs because of concerns about the possible damaging misappropriation of their own resources by CVCs ( Katila , Rosenberger , and Eisenhardt 2008 ; Maula , Autio , and Murray 2009 ) . In these strands of literature , it is not fully examined how a start - up ‚Äô s product development stage impacts its choice on financing sources and how this choice evolves as the product development process proceeds . This examination is important because technology is often the most important resource pursued by a start - up and it is dynamic by the nature . In particular , I argue that a start - up may select a type of investors according to the availability of investors and the nature of complementary assets provided by investors . These two factors can evolve along with a start - up ‚Äô s product development cycle . This perspective also extends prior studies that are based on the arbitrary role of investors in matching between investors and investees ( e . g . , Fulghieri and Sevilir 2009 ; Hellmann 2002 ) . A start - up may be able to be an active decision - maker depending on the technological status . Some observations in the literature have indirectly indicated this possibility . For example , an investor does not always get its first - choice investment opportunity ( Gompers 2002 ; Hsu 2004 ; Santos and Eisenhardt 2009 ) and often pays much more by investing in overvalued transactions ( Benson and Ziedonis 2010 ; Gompers and Lerner 2000a ) . In addition , a start - up has the greatest flexibility to choose among potential investors or simply avoid investment ties with some investors ( Katila , Rosenberger , and Eisenhardt 2008 ; Maula , Keil , and Zahra 2013 ; Stuart , Hoang , and Ralph 1999 ) . 2 . 2 Hypotheses Development As a start - up accumulates its technology in its life cycle , it is likely to become more competent to complete its product development process by reducing uncertainty around the technology , allowing it to become an at - tractive investee or have a wider range of investor pool in the entrepreneurial finance market . Moreover , the accumulation of technological expertise enables a start - up to better understand and recognize the value of the technology and the nature of necessary resources for future uses . As a start - up enters into a more matured development stage , it is more likely to search local and neighborhood information , and elicit its existing knowl - edge stores to achieve an immediate advantage ( Levinthal and March 1993 ) . This notion is consistent with some empirical evidence in the biopharmaceutical industry ( e . g . , Rothaermel and Deeds 2004 ) . This self - reinforcing practice makes a start - up more efficient in optimizing its financing arrangements , reducing the costs of under - taking such initiatives and allowing a start - up to become more attractive ( Dyer and Singh 1998 ; Basu , Phelps , and Kotha 2011 ) . Hence , it is assumed that a dynamic relationship between a start - up ‚Äô s technological progress and a suitable pool of investors exists in a start - up ‚Äô s life cycle ( Schwienbacher 2013 ) . In the biopharmaceutical industry , there are common and distinguishable product development stages de - fined by the U . S . Food and Drug Administration ( FDA ) drug review process ( see Table 5 ) . The drug develop - ment stages are classified into the preclinical , phase I , phase II , and phase III . 2 The transition probabilities for advancing to the next stage are 0 . 71 , 0 . 44 , and 0 . 69 in Phase I , II , and III ( Grabowski and Kyle 2008 ) . This process from discovery to approval is uniquely long , averaging between 10 and 12 years , compared with an average of 6 ‚Äì 18 months in other high technology sectors ( Griffin 2002 ) . These unique characteristics , including long prod - uct development process and a great amount of necessary capital , costly prohibit a start - up from developing a drug by completely itself . A start - up is likely to need a different resource set to proceed its product development in each stage . For example , drug discovery often starts with ideas for a drug target and a lead molecule in the preclinical stage . The choice of target ( e . g . , a cell surface receptor involved in sending messages into the cell nucleus or a messenger molecule that binds to receptors as a ligand ) is driven by a start - up ‚Äô s understanding of the biology of a particular disease . Once a lead compound has been identified , a start - up proceeds to the preclinical stage , which comprises 4 A u t o m a t i c a ll y g e n e r a t e d r o u g hP D F b y P r oo f C h e c k f r o m R i v e r V a ll e y T e c h n o l o g i e s L t d DEGRUYTER Kang various tests in vitro as well as in relevant animal models . These earlier steps in the product development process are multi - year processes and often requires millions of dollars , which is a comparably smaller amount of cost relative to the following clinical stages . As a start - up reaches a certain threshold of technological progress , its position in the entrepreneurial finance market becomes better to finance its projects and the necessary amount of capital becomes larger , too . As noted , a start - up needs to finance relatively a smaller amount of capital in the preclinical stage , com - pared with the following clinical stages , including phase I , phase II , and phase III . As a result , a business angel can be a suitable financing source in this stage because it is more readily accessible than institutional investors are and tends to provide a smaller amount of capital ( Puri and Zarutskie 2012 ; Hellmann and Thiele 2015 ; Dutta and Folta 2016 ) . As a start - up proceeds its development process , it becomes to need more financial and non - financial resources beyond the ranges that angels can provide ( Jensen 1993 ) . Consequently , angels are not likely to become a suitable type of investor in the following clinical stages . However , some angels exceptionally continue to finance in the following stages by joining with an angel group that combines individual angels ‚Äô commitments and thus invests a greater amount of capital . In essence , an angel ‚Äô s availability and commitment captures a conventional wisdom that a start - up tends to finance its project from angels in its early stage of prod - uct development process . This start - up continuously seeks financing opportunities from institutional investors as it proceeds to the following product development stages . Hypothesis 1 A start - up is more likely to finance its projects from business angels in the early stages of product development cycle ( e . g . , preclinical stage and phase I ) and less likely to do in the following stages of product development cycle ( e . g . , phase II and phase III ) . Due to the complexity of uncertainty , it is not feasible for any start - up to identify and study a target and lead compound internally ( e . g . , in - house ) . For example , a start - up cannot resolve exogenous uncertainty ( e . g . , technological advancements in relevant fields ) with its own effort , and thus needs to focus its process to resolve endogenous uncertainty . In contrast , internal uncertainty can be resolved within collaborative networks that include incumbent pharmaceutical corporations ( i . e . , CVCs ) . These corporations also play as an alternative financing source and may contribute to resolve exogenous uncertainty by providing complementary assets for drug approval process , industrial networks , marketing channels , and necessary human capital ( Park and Steensma 2011 ) . CVCs often seek investment opportunities to pursue not only capital gains but also technology spillovers from exposure and access to external technologies . These technology spillovers may redirect and guide their internal R & D activities through observing the technological trajectories mapped by start - ups , resolving their own technological challenges . Given these mutual needs between CVCs and start - ups , CVCs become a suitable type of investors to finance a start - up ‚Äô s project in the early stage of product development ( e . g . , preclinical stage and phase I ) . In these stages , CVCs can preempt the focal technology by becoming a stock holder of the start - up , whereas the start - up can start to build industrial networks that help proceed the following development stages . This match is impacted by technological complementarity between two partners ( Ceccagnoli , Higgins , and Kang 2014 ) . This notion is consistent with the recent finding ( Alvarez - Garrido and Dushnitsky 2015 ) that start - ups backed by CVCs experience higher rates of innovation outputs , compared to those backed by IVCs ; and the performance of these start - ups is sensitive to their ability to FDA approval requirements as the mechanisms associated with CVC contribution . As a start - up reaches a certain threshold ( e . g . , phase II and phase III ) , CVCs still may want to have a better position in the relationship with start - ups to utilize their down - stream assets . These assets include research facilities , distribution channels , marketing experiences , and necessary resources to facilitate a drug approval process . These down - stream assets are specified in the current research programs , which are in part replaced by a genetic engineering based product development process . As long as a start - up ‚Äô s technology is promising enough to justify CVCs ‚Äô time and attention , CVCs will be willing to invest in the start - up for such strategic motives . This start - up also needs complementary assets provided by CVCs to successfully complete its product development process and eventually launch the product in the market . In the later stages , a promising start - up has a wider pool of investors ( Hsu 2004 ) and is able to attract CVCs , too . In addition , there is a greater chance that a start - up finances its project from syndicated investors combining CVCs and IVCs in the later stages . These syndicated investors may lead to better decisions about whether and where to invest in by reducing information asymmetries ( Sah and Stiglitz 1986 ; Adamati and Pfleiderer 1994 ) . Syndicated investments are preferred by both types of investors because investors want to have a chance to check out their own thinking against other knowledgeable resources ( Perez 1986 ) . Syndicated investments also provide a greater pool of capital for current and follow - on cash needs as well as technological and managerial supports , which are often complementary to each other . Hence , I predict : Hypothesis 2 A start - up is more likely to finance its projects from CVCs in the early stages of product development cycle ( e . g . , preclinical stage and phase I ) and continue to finance its projects from solely CVCs or syndicated investors combining CVCs and IVCs in the following stages of product development cycle ( e . g . , phase II and phase III ) . 5 A u t o m a t i c a ll y g e n e r a t e d r o u g hP D F b y P r oo f C h e c k f r o m R i v e r V a ll e y T e c h n o l o g i e s L t d Kang DEGRUYTER Unlike CVCs that are willing to finance a start - up in all the stages of product development cycle , IVCs are more likely to invest in the early stages of it due to their own structure and services provided for a start - up . IVCs raise capital from limited partners to organize their funds . These funds typically have a fixed life of 10 years and are compensated with a fraction of the capital gains as well as fixed management fees ( Sahlman 1990 ; Alvarez - Garrido and Dushnitsky 2015 ) . Within this typical structure , IVCs ‚Äô payoffs are determined by a start - up ‚Äô s market potential , which often positively correlated with uncertainty residing in completing the product development process . As a result , IVCs necessarily seek investment opportunities in a niche market characterized by high uncertainty and possibly high rates of return ( Amit , Brander , and Zott 1998 ) , which captures a start - up that pursues the early stages of product development process . It is also noteworthy that the value of managerial supports provided by IVCs is more salient for a start - up in the early stages of product development process . Specifically , there are three types of the managerial supports : monitoring , professionalization , and certification ( Denis 2004 ) . 3 As a start - up reaches a more matured threshold in its product development cycle , these managerial supports become less important and a different set of resources ( e . g . , resources for the drug approval process and marketing channels ) is more importantly required to successfully complete the product development process . These resources may be directly provided by CVCs in an efficient manner ( Gans , Hsu , and Stern 2002 ) rather than IVCs that can ‚Äô t emulate these services . As IVCs become less capable investors in the later stages of product development process , they may want to seek syndicated investment opportunities with CVCs . These investments are not likely to provide a chance of ‚Äú swing for the fence ‚Äù but a higher chance of harvesting by subsequent exits . Hypothesis 3 A start - up is more likely to finance its projects from IVCs in early stages of product development cycle ( e . g . , preclinical stage and phase I ) and continue to finance its projects from syndicated investors combining CVCs and IVCs rather than solely IVCs in the following stages of product development cycle ( e . g . , phase II and phase III ) . 3 Data and Empirical Method 3 . 1 Data To test my hypotheses on the dynamics of a start - up ‚Äô s financing decisions associated with its R & D stages , I col - lected a set of longitudinal financing records of biopharmaceutical start - ups from the Deloitte ReCap database between 1985 and 2006 , which was a period of significant expansion in external fundraising activities in this industry ( e . g . , MacMillan et al . 2008 ; National Venture Capital Association 2010 ) . This database collects data on biotechnology based start - ups ‚Äô financing and alliances from three primary sources : biopharmaceutical com - pany press releases and other literature ; U . S . Securities and Exchange Commission filings ; and company pre - sentations made at investment conferences and other public meetings . This collection includes all the start - ups that have actively operated during the period regardless whether they successfully have gone IPOs or not . By including both successful and failed start - ups , this study focuses on what biopharmaceutical start - ups actu - ally do rather than what they should do . No one of publicly available biopharmaceutical databases , including SDC database , MERIT - CATI database , and Bioscan database , can be considered to contain the population of financing and alliance activities . However , out of the many databases , the Deloitte ReCap is the most suitable database in terms of the consistency of coverage and completeness ( Schilling 2009 ) . A subset of this database tracks round - by - round financing records through the entire life cycles of start - ups from founding to final dispo - sition over 700 biopharmaceutical start - ups . This information includes financing records from any individual investors ( i . e . , angels ) , private equity investors ( i . e . , IVCs ) , equity alliances with incumbents ( i . e . , CVCs ) , and other investors such as hospitals , universities , and research labs . I include start - ups that had any financing records found from any source in their entire life cycles . Since this study is focused on the entire cycle of prod - uct development , which takes , on average , 10 to 12 years and often contains a time period of a start - up ‚Äô s IPO , I also included financing records after a start - up goes public . For each of the start - ups , I reconstructed its drug pipeline using data from the PharmaProjects database . PharmaProjects is a proprietary database ( https : / / citeline . com / products / pharmaprojects ) containing informa - tion updated monthly on drugs in development since 1980 . Each drug profile in the database includes the drug ‚Äô s current status , the original materials , the primary therapy , the primary indication and other indications , route of administration , the name of the developing firm , the country where it is being developed , the novelty rating , and other information . PharmaProjects is compiled from both published and unpublished sources , including information obtained directly from the companies involved in product development . In order to characterize several dimensions of a start - up ‚Äô s technology I utilized patent data obtained from the NBER U . S . Patent Citations Data File , which tracks the change of patent ownership in the sample period . This source helps create variables related with a start - up ‚Äô s patenting activities , including patents , forward citations , 6 A u t o m a t i c a ll y g e n e r a t e d r o u g hP D F b y P r oo f C h e c k f r o m R i v e r V a ll e y T e c h n o l o g i e s L t d DEGRUYTER Kang and backward citations . The role of patenting is particularly relevant in this industry given that a start - up is highly likely to patent its inventions to protect its intellectual property ( Cohen , Nelson , and Walsh 2000 ) . Variable descriptions and the source of information are presented in Appendix A . All the nominal values are deflated by the Current Consumer Price Index ( CPI - U ) published by the Bureau of Labor Statistics and are in constant 2006 U . S . dollars . The synthesis of multiple data sources , which do not contain all the observations cross the sources , makes several missing observations . Finally , my sample contains 1306 fundraising activities involved with 113 biopharmaceutical start - ups , corresponding to 261 business angels , 170 IVCs , 296 CVCs , and 26 syndicated investors containing both CVCs and IVCs , and 553 other investors . 3 . 2 Dependent Variable : Financing Source For an outcome variable of my analysis , the dependent variable is the financing source ( i . e . , ùë¶ ùëñ ) , which denotes each type of investors in the funding round . ùë¶ ùëñ = 1 corresponds to a start - up ‚Äô s financing from angles with the time subscript omitted ; ùë¶ ùëñ = 2 does from IVCs ; ùë¶ ùëñ = 3 does from CVCs ; ùë¶ ùëñ = 4 does from syndicated investors containing CVCs and IVCs ; ùë¶ ùëñ = 0 does from other investors . As a result , my dependent variable becomes a discrete variable and the distribution of this variable is presented in Table 2 . Major CVCs and IVCs are presented in Appendix B ; and sample distribution over time is presented in Appendix C . In the definition of variable , it is noteworthy that ùë¶ ùëñ = 4 does not denote simply multiple investors in the funding round , but denotes syndicated investors containing both CVCs and IVCs in the group of investors . For example , my data indicates that 243 rounds are financed by more than one investors ( i . e . , multiple investors ) , but only 26 out of those 243 are financed by syndicated groups that contain both CVCs and IVCs . Table 1 : Summary statistics . Panel A : Descriptive statistics ‚Äì Financing source and number of products within R & D stages All sample Number of products ( preclinical ) Number of products ( phase I ) Number of products ( phase II ) Number of products ( phase III ) Number of products ( launched ) N % Mean SD Mean SD Mean SD Mean SD Mean SD 1 . ùë¶ 1 ( Angel ) 261 20 0 . 521 1 . 952 0 . 103 0 . 457 0 . 126 0 . 571 0 . 053 0 . 272 0 . 011 0 . 107 2 . ùë¶ 2 ( IVC ) 170 13 0 . 400 1 . 630 0 . 105 0 . 555 0 . 082 0 . 467 0 . 029 0 . 201 0 . 011 0 . 153 3 . ùë¶ 3 ( CVC ) 296 23 1 . 557 3 . 238 0 . 324 0 . 813 0 . 310 0 . 822 0 . 199 0 . 580 0 . 040 0 . 244 4 . ùë¶ 4 ( Syndication ) 26 2 0 . 000 0 . 000 0 . 076 0 . 392 0 . 384 0 . 852 0 . 076 0 . 392 0 . 000 0 . 000 5 . ùë¶ 0 ( Other ) 553 42 0 . 330 1 . 654 0 . 072 0 . 495 0 . 086 0 . 481 0 . 032 0 . 188 0 . 001 0 . 043 Total 1306 100 0 . 649 2 . 209 0 . 150 0 . 589 0 . 140 0 . 606 0 . 075 0 . 344 0 . 013 0 . 140 Panel B : Descriptive statistics ‚Äì Variables All sample N Mean SD Min . Max . 1 . Financing selection Financing source 1306 1 . 219 1 . 262 0 . 000 4 . 000 2 . Products within R & D stages Number of products ( preclinical ) 1306 0 . 649 2 . 209 0 . 000 28 . 000 Number of products ( phase I ) 1306 0 . 150 0 . 589 0 . 000 8 . 000 Number of products ( phase II ) 1306 0 . 140 0 . 606 0 . 000 6 . 000 Number of products ( phase III ) 1306 0 . 075 0 . 344 0 . 000 4 . 000 Number of products ( launched ) 1306 0 . 013 0 . 140 0 . 000 2 . 000 Ratio of products ( preclinical ) 1306 0 . 090 0 . 252 0 . 000 1 . 000 Ratio of products ( phase I ) 1306 0 . 026 0 . 101 0 . 000 1 . 000 Ratio of products ( phase II ) 1306 0 . 023 0 . 119 0 . 000 1 . 000 Ratio of products ( phase III ) 1306 0 . 016 0 . 094 0 . 000 1 . 000 Ratio of products ( launched ) 1306 0 . 004 0 . 063 0 . 000 1 . 000 3 . Firm characteristics Age 1306 6 . 347 5 . 149 0 . 000 23 . 764 Patents 1306 15 . 951 46 . 103 0 . 000 651 . 000 Forward citations 1306 138 . 467 454 . 162 0 . 000 4090 . 000 Backward citations 1306 183 . 141 679 . 006 0 . 000 7693 . 000 External R & D 1306 13 . 566 16 . 930 0 . 000 120 . 000 4 . Financing characteristics Funding amount 1306 2 . 115 1 . 554 ‚àí 4 . 605 6 . 916 Cumulative funding amount 1306 3 . 455 1 . 918 ‚àí 1 . 050 7 . 304 Financing experience 1306 6 . 039 4 . 509 0 . 000 22 . 000 7 A u t o m a t i c a ll y g e n e r a t e d r o u g hP D F b y P r oo f C h e c k f r o m R i v e r V a ll e y T e c h n o l o g i e s L t d Kang DEGRUYTER Prior IVC 1306 0 . 531 0 . 499 0 . 000 1 . 000 Prior CVC 1306 0 . 693 0 . 461 0 . 000 1 . 000 5 . Fixed effects Firm fixed effects 1306 1 . 000 0 . 000 0 . 000 1 . 000 Year fixed effects 1306 1 . 000 0 . 000 0 . 000 1 . 000 3 . 3 Key Explanatory Variables : Number of Products within R & D Stages By the nature of technological progress , which is developed over time and accumulated through past expe - riences , it is hard to clearly distinguish a start - up ‚Äô s R & D stages in many high - tech industries . However , I am fortunately able to use a specific drug approval process administered by U . S . Food and Drug Administration ( FDA ) in my setting . Since the revenue streams of biopharmaceutical firms are dependent upon the flow of new products , I used data from drug pipelines to measure the progress of product development process . The drug pipelines , by nature , may represent the dynamics of a start - up ‚Äô s lifespan . Within a start - up ‚Äô s R & D pipeline I count the number of drugs being developed in each stage , including preclinical stage , phase I , phase II , and phase III at year t . Thus , my key independent variables are a set of number of products in four stages . These variables provide several advantages to test my hypotheses . First , this measure directly estimates a start - up ‚Äô s technological progress ( e . g . , dynamics in a start - up ‚Äô s growth ) by focusing on the outcomes of R & D activities . Second , unlike financial accounting variables , this measure can be applied to any start - up regardless of its IPO status . Finally , this clinical development process is a common path to commercialize any product in the in - dustry as well as consume most product development costs . For example , preclinical drug discovery accounts for approximately 32 % of the costs for a new drug , and clinical development ( i . e . , phase I through phase III ) accounts for approximately 63 % ( Paul et al . 2010 ) . While I believe this set of variables is suitable to estimate a start - up ‚Äô s technology status in my setting , this measure also has a concern to be used . Given that the unit of analysis entails each start - up ‚Äô s development capability of varying sizes , I should carefully control for any potential size - effects on a start - up ‚Äô s financing choices and influential outliers in the following empirical analysis . To address these concerns I have also created a set of normalized variables that correspond to the number of products in each stage . For example , ratio of products ( preclinical ) is calculated by the ratio of the number of products in the preclinical stage to total number of products in all the stages at t . The ratio variables in the following stages are created in a similar manner . 3 . 4 Control Variables 3 . 4 . 1 Start - Up ‚Äô s Age Age can help firms become more efficient in such a way that learning can occur as a by - product of day - to - day activities ( Bhak and Gort 1993 ) . This condition , if unobserved , may be confounded with my variables of interest . I compute age by the number of days from a start - up ‚Äô s founding to t , divided by 365 . 3 . 4 . 2 Patents Some studies have reported that a start - up ‚Äô s patenting capacity is positively correlated with the amount of its external financing received ( e . g . , Baum and Silverman 2004 ; Mann and Sager 2007 ) . Thus , I estimate patents by using a start - up ‚Äô s patent stock at t ( Hall , Jaffe , and Trajtenberg 2005 ) and include it in the following analysis . 3 . 4 . 3 Citations Forward citations are the citations that a patent receives from subsequent patents . The number of forward citations has been shown to be positively related with the value of patents and often used to control for the potential value of a start - up ‚Äô s technology in the literature ( Dyer and Singh 1998 ) . Since the value of technology is heterogeneously distributed and impacts a start - up ‚Äô s financing decisions , I control for it using forward citations that counts a start - up ‚Äô s forward citation stock at t . In contrast , backward citations that a patent cites previous patents are involved with technological uncer - tainty that may serve as a proxy for a reciprocal for commercial potential in high - technology sectors ( Iansiti 1995 ; Krishnan and Bhattacharya 2002 ) . This uncertainty is likely to be higher for technology that is more basic 8 A u t o m a t i c a ll y g e n e r a t e d r o u g hP D F b y P r oo f C h e c k f r o m R i v e r V a ll e y T e c h n o l o g i e s L t d DEGRUYTER Kang or more distant from commercialization ( Ziedonis 2007 ) . I estimate this nature of technology using backward citations that counts a start - up ‚Äô s backward citation stock at t ( Lanjouw and Schankerman 2001 ) . The greater backward citations represent the more matured technology , and vice versa . 3 . 4 . 4 External R & D A start - up that has already participated in a wide range of industrial networks with external R & D activities is likely to pursue a financing opportunity existing within the networks . I control for the distribution of external R & D experiences using external R & D that is estimated by the stock of collaborative research alliances , licensing contracts , and other types of technological alliances at t . 3 . 4 . 5 Funding Amount and Cumulative Funding Amount Since investors have a heterogeneous distribution of funding capacities , I control for funding amount measured by the log of amount of financing in million U . S . dollars . More specifically , unlike institutional investors who manage the pooled capital on behalf of other investors in the funds , an angel often invests its own fund so its investment is typically much smaller than that of institutional investors ( Gompers 1995 ) . Consequently , a start - up that seeks a greater amount of capital is likely to exploit a funding opportunity from institutional investors . These growth effects are controlled by using cumulative funding amount that is calculated by the log of cumulative amount of financing in million U . S . dollars . 3 . 4 . 6 Financing Experience , Prior CVC , and Prior IVC Due to the learning effects , a start - up that has previously financed from a certain type of investors is likely to access the same type of investors ( Cooley and Smith 1998 ) . I control for this path dependency using a set of variables , including financing experience , prior CVC , and prior IVC . Financing experience is estimated by the number of prior fundraising activities at t . Prior CVC and prior IVC are indicator variables that equal to one if a start - up has previously financed from IVCs ( i . e . , prior IVC ) and CVCs ( i . e . , prior CVC ) , and zero otherwise . 3 . 4 . 7 Firm and Year Fixed Effects I include two fixed effects estimators , including firm and year fixed effects , in the following analyses . Firm fixed effects are a set of dummy variable that corresponds to each firm and control for time - invarying factors such as a start - up ‚Äô s origin ( e . g . , university or corporation spinoff or endogenous entrepreneur ) , founding team char - acteristic , and project characteristic ( Schwienbacher 2013 ; Vanacker , Meuleman , and Manigart 2014 ) . Year fixed effects control for any variation in the outcome that happen over time and that is not attributed to explanatory variables . This variable corresponds to each t . 3 . 5 Empirical specifications To test my hypotheses , I utilize several econometric approaches based on multinomial logit regression . The multinomial logit regression , which has been popular due to its simplicity and applicability , generalizes lo - gistic regression to more than two possible discrete outcomes ( Greene 1993 ) . In this specification , I estimate the following model : ( ùë¶ ùëñ = ùëó | ùëç ùëñ ) = ùëí ùëç ùëñ ùõø ùëó ‚àë 5 ùëò = 1 ùëí ùëç ùëñ ùõøùëò , ùëó ‚àà { 1 , 2 , 3 , 4 , 0 } , where ùë¶ ùëñ denotes financing source , and ùëç ùëñ are explanatory variables . The independent variables of interest are a set of variables that estimate the number of products being developed in each R & D stage , including number of products ( preclinical ) , number of products ( phase I ) , number of products ( phase II ) , number of products ( phase III ) , number of products ( launched ) . Control variables in - clude age , patents , forward citations , backward citations , external R & D , funding amount , cumulative funding amount , financing experience , prior IVC , prior CVC , and firm and year fixed effects . This approach , however , provides only supportive evidence because it may violate the independence of irrelevant alternatives ( IIA ) assumption applied in the multinomial logit specification ( Manski and McFadden 1981 ) . For example , both CVCs and IVCs are scarce relative to angel financing ( Freear , Sohl , and Wetzel 1996 ; Prowse 1998 ) so a start - up may first finance its projects from an angel and subsequently finance from CVCs and 9 A u t o m a t i c a ll y g e n e r a t e d r o u g hP D F b y P r oo f C h e c k f r o m R i v e r V a ll e y T e c h n o l o g i e s L t d Kang DEGRUYTER IVCs . Given this sequence of decision making , the components of error terms of IVCs and CVCs financing can be correlated , violating the IIA assumption . As a corollary and unreported analysis , I performed the IIA test by adding or deleting alternative outcome categories and found that this practice does not affect the odds among the remaining outcomes . As a result , the multinomial logit specification becomes suitable in our setting . To provide a better visualization , I provide the rank orders of financing sources that a start - up is likely to choose in each product development stage . Since the regression coefficients of multinomial logit regressions are not easily interpreted , this rank can provide an intuitively understandable result . In addition , I perform a test if a set of independent variables of interest are statistically significant . This test is necessary to confirm whether or not the R & D stages of start - up are necessarily related with the decision making on financing sources . To refine the issue of the unit of analysis involved with a start - up ‚Äô s number of products of varying sizes , I use a set of normalized measures in the next sensitivity analysis . This set of variables include ratio of products ( preclinical ) , ratio of products ( phase I ) , ratio of products ( phase II ) , ratio of products ( phase III ) , and ratio of products ( launched ) . As noted , these variables are estimated by the ratio of the number of products in each stage divided by the total number of products in all the stages at t . 4 Empirical Findings 4 . 1 Descriptive Statistics The descriptive statistics are presented in Table 1 . In Panel A , all sample includes 1306 entrepreneurial financing activities and are categorized into five groups along with the outcomes of financing source , including ùë¶ 1 ( Angel ) , ùë¶ 2 ( IVC ) , ùë¶ 3 ( CVC ) , ùë¶ 4 ( Syndication ) , and ùë¶ 0 ( Other ) . The columns report the distribution of observations and the summary statistics along with a set of independent variables , including number of products ( preclinical ) , number of products ( phase I ) , number of products ( phase II ) , number of products ( phase III ) , and number of products ( launched ) . For the completeness of analysis number of products ( launched ) is included in the following empirical analyses . The first column reports the distribution of observations : ùë¶ 1 is 261 observations and 20 % of the sample ; ùë¶ 2 is 170 observations and 13 % of the sample ; ùë¶ 3 is 296 observations and 23 % of the sample ; ùë¶ 4 is 26 observations and 2 % of the sample ; and ùë¶ 0 is 553 observations and 42 % of the sample . The small portion of angel financing , relative to that in other high - tech industries , is probably due to the nature of biopharmaceutical industry where a large amount of product development cost , which is often beyond the range of angels , is required to complete the product development process in a highly uncertain setting . As noted , a syndication is defined as an investor group that contain both IVCs and CVCs . A group of investors who fall into either type of IVCs or CVCs is categorized into each type . This narrow definition allows me to have a small portion of syndication in my sample . The proportions of IVCs and CVCs are slightly lower than those of 63 other high - tech industries , which are , on average , 20 % to 30 % ( Guo , Lou , and Perez - Castrillo 2011 ) . This occurs because other types of investors , including universities , leading labs , and hospitals , actively invest in the product development process that is closely involved with scientific discoveries in this industry . The following columns indicate a notable pattern that the number of products being developed within a start - up ‚Äô s R & D pipeline is diminished as the stage of product development proceeds . This pattern is commonly observed regardless of funding resources . It is noteworthy that ùë¶ 1 and ùë¶ 3 have a considerably greater number of products in preclinical stage followed by ùë¶ 2 and ùë¶ 4 , which is consistent with hypotheses 1 and 2 . In contrast , ùë¶ 2 has more products in phase I than ùë¶ 1 does , indicating that a start - up is more likely to finance its projects from IVCs in phase I as predicted in hypothesis 3 . It is also notable that ùë¶ 3 has considerably a greater number of products than any other groups throughout all the product development stages ; and ùë¶ 4 does in phase II and phase III . These statistics are collectively consistent with my predictions made in hypotheses 1 , 2 , and 3 . Due to the nature of industry that necessarily takes long time and requires various complementary assets in the product development process , CVCs and syndicated investors play a central role in providing necessary assets and capital for start - ups . However , these statistics need to be interpreted with caution because they are simply univariate results and may be biased due to unobserved heterogeneity . Panel B reports summary statistics for the five groups of variables used in the following analysis . These groups include financing selection , products within R & D stages , firm characteristics , financing characteristics , and fixed effects that control for time - invarying and yearly factors . It is notable that a set of ratio of products is diminished as a start - up ‚Äô s product development process proceeds . This is consistent with the pattern shown with a set of number of products . This consistency in part reduces a concern of normalization issue . Firm characteristics and financing characteristics provides a set of dimensions of sample . Start - ups in the sample are , on average , 6 . 34 - years old and have , on average , 15 . 91 stock of patents at t . These statistics indicate that my sample are typically young and actively pursue patenting capacities when they finance their projects from external sources . These 10 A u t o m a t i c a ll y g e n e r a t e d r o u g hP D F b y P r oo f C h e c k f r o m R i v e r V a ll e y T e c h n o l o g i e s L t d DEGRUYTER Kang start - ups have experienced , on average , 13 . 56 alliances , 6 . 03 prior funding rounds , and raised $ 8 . 28 million U . S . dollars per round . The correlations of all the variables are presented in Appendix D . 4 . 2 A Start - Up ‚Äô s Financing Choice Table 2 presents my benchmark results obtained from multinomial logit regressions . To ensure model identifi - cation in the regressions ùë¶ 0 is set to a base group and its regression coefficients ( e . g . , zeroes ) are not presented in the table . All the regression coefficients should be interpreted by comparing with those of base group ( i . e . , zeroes ) and across other groups . The absolute magnitudes of regression coefficients are not always meaning - ful . For example , in Model 1 that includes all the control variables , a positive regression coefficient of age in ùë¶ 1 ( i . e . , 0 . 086 ) can be interpreted that a start - up tends to finance its projects from ùë¶ 1 rather than ùë¶ 0 as it becomes older . Since the regression coefficient of age in ùë¶ 3 is negative ( i . e . , ‚àí 0 . 116 ) and smaller than those in any other groups , it indicates that a younger start - up tends to finance its projects from ùë¶ 3 rather than any other groups , suggesting that CVCs actively pursue investment opportunities in young start - ups in this industry . Patents in - dicate significant and positive regression coefficients in ùë¶ 2 and ùë¶ 3 . This result is consistent with a notion from biopharmaceutical industry executives that a start - up ‚Äô s patenting capacity is necessary to attract investments from IVCs and CVCs . This result is not necessarily consistent in the contexts of other high - tech industries that have much quicker product development processes and possibly develop designing around patents . Table 2 : Financing source and number of products within R & D stages . Fixed effects multinomial logit regression Model ( 1 ) ( 2 ) ùë¶ ùëñ 1 2 3 4 1 2 3 4 Number of products ( preclinical ) 0 . 036 0 . 094 0 . 138 * * * ‚àí 12 . 739 ( 0 . 061 ) ( 0 . 083 ) ( 0 . 051 ) ( 545 . 302 ) Number of products ( phase I ) ‚àí 0 . 215 0 . 497 * ‚àí 0 . 209 ‚àí 0 . 961 ( 0 . 230 ) ( 0 . 283 ) ( 0 . 206 ) ( 1 . 705 ) Number of products ( phase II ) ‚àí 0 . 116 ‚àí 0 . 141 0 . 104 1 . 802 * * ( 0 . 189 ) ( 0 . 341 ) ( 0 . 186 ) ( 0 . 728 ) Number of products ( phase III ) 0 . 197 0 . 010 0 . 946 * * * 1 . 531 ( 0 . 381 ) ( 0 . 664 ) ( 0 . 357 ) ( 1 . 127 ) Number of products ( launched ) 1 . 258 1 . 953 1 . 587 ‚àí 16 . 684 ( 1 . 143 ) ( 1 . 198 ) ( 1 . 079 ) ( 1 . 0e + 04 ) Age 0 . 086 * * * ‚àí 0 . 051 ‚àí 0 . 116 * * * 0 . 083 0 . 087 * * * ‚àí 0 . 037 ‚àí 0 . 106 * * * 0 . 030 ( 0 . 027 ) ( 0 . 059 ) ( 0 . 033 ) ( 0 . 143 ) ( 0 . 027 ) ( 0 . 061 ) ( 0 . 034 ) ( 0 . 165 ) Patents 0 . 001 0 . 014 * * 0 . 009 * * * ‚àí 0 . 043 0 . 001 0 . 013 * * 0 . 007 * ‚àí 0 . 035 ( 0 . 003 ) ( 0 . 006 ) ( 0 . 003 ) ( 0 . 046 ) ( 0 . 003 ) ( 0 . 006 ) ( 0 . 003 ) ( 0 . 041 ) Forward citations 0 . 000 ‚àí 0 . 002 * * 0 . 001 0 . 001 0 . 000 ‚àí 0 . 003 * * 0 . 001 0 . 001 ( 0 . 000 ) ( 0 . 001 ) ( 0 . 000 ) ( 0 . 003 ) ( 0 . 000 ) ( 0 . 001 ) ( 0 . 000 ) ( 0 . 003 ) Backward citations ‚àí 0 . 000 0 . 001 ‚àí 0 . 001 * * * ‚àí 0 . 001 ‚àí 0 . 000 0 . 001 ‚àí 0 . 001 * * * ‚àí 0 . 001 ( 0 . 000 ) ( 0 . 001 ) ( 0 . 000 ) ( 0 . 003 ) ( 0 . 000 ) ( 0 . 001 ) ( 0 . 000 ) ( 0 . 002 ) External R & D 0 . 002 ‚àí 0 . 012 0 . 018 * * * 0 . 021 0 . 001 ‚àí 0 . 022 0 . 011 0 . 033 ( 0 . 006 ) ( 0 . 014 ) ( 0 . 007 ) ( 0 . 036 ) ( 0 . 006 ) ( 0 . 015 ) ( 0 . 007 ) ( 0 . 043 ) Funding amount ‚àí 0 . 668 * * * ‚àí 0 . 153 ‚àí 1 . 232 * * * 0 . 292 ‚àí 0 . 679 * * * ‚àí 0 . 092 ‚àí 1 . 205 * * * 0 . 028 ( 0 . 095 ) ( 0 . 170 ) ( 0 . 110 ) ( 0 . 444 ) ( 0 . 096 ) ( 0 . 172 ) ( 0 . 113 ) ( 0 . 450 ) Cumulative funding amount 0 . 633 * * * ‚àí 0 . 893 * * * 0 . 527 * * * ‚àí 2 . 089 * * * 0 . 642 * * * ‚àí 0 . 943 * * * 0 . 426 * * ‚àí 1 . 869 * * * ( 0 . 117 ) ( 0 . 269 ) ( 0 . 160 ) ( 0 . 629 ) ( 0 . 119 ) ( 0 . 273 ) ( 0 . 168 ) ( 0 . 683 ) Financing experience ‚àí 0 . 006 ‚àí 0 . 064 ‚àí 0 . 036 ‚àí 0 . 294 ‚àí 0 . 004 ‚àí 0 . 075 ‚àí 0 . 022 ‚àí 0 . 303 ( 0 . 037 ) ( 0 . 081 ) ( 0 . 046 ) ( 0 . 238 ) ( 0 . 037 ) ( 0 . 082 ) ( 0 . 048 ) ( 0 . 272 ) Prior IVC ‚àí 0 . 632 * * * 22 . 838 ‚àí 0 . 300 20 . 629 ‚àí 0 . 643 * * * 23 . 875 ‚àí 0 . 262 21 . 295 ( 0 . 195 ) ( 598 . 305 ) ( 0 . 209 ) ( 1157 . 055 ) ( 0 . 196 ) ( 982 . 408 ) ( 0 . 216 ) ( 1730 . 195 ) Prior CVC ‚àí 0 . 189 ‚àí 0 . 602 * 20 . 136 19 . 499 ‚àí 0 . 196 ‚àí 0 . 629 * * 21 . 215 19 . 304 ( 0 . 241 ) ( 0 . 316 ) ( 805 . 384 ) ( 1728 . 834 ) ( 0 . 242 ) ( 0 . 319 ) ( 1312 . 788 ) ( 1638 . 353 ) Constant ‚àí 1 . 771 * * * ‚àí 18 . 128 ‚àí 18 . 501 ‚àí 33 . 736 ‚àí 1 . 774 * * * ‚àí 19 . 143 ‚àí 19 . 474 ‚àí 34 . 356 ( 0 . 197 ) ( 598 . 304 ) ( 805 . 384 ) ( 2080 . 297 ) ( 0 . 198 ) ( 982 . 407 ) ( 1312 . 788 ) ( 2382 . 807 ) Firm fixed effects Yes Yes Yes Yes Yes Yes Yes Yes Year fixed effects Yes Yes Yes Yes Yes Yes Yes Yes N 1306 1306 Log likelihood ‚àí 1 . 1e + 03 ‚àí 1 . 1e + 03 Prob \ gt œá 2 0 . 000 0 . 000 11 A u t o m a t i c a ll y g e n e r a t e d r o u g hP D F b y P r oo f C h e c k f r o m R i v e r V a ll e y T e c h n o l o g i e s L t d Kang DEGRUYTER pseudo R 2 0 . 373 0 . 391 Notes . ùë¶ ùëñ includes ùë¶ 1 = angel , ùë¶ 2 = IVC , ùë¶ 3 = CVC , ùë¶ 4 = syndication , and ùë¶ 0 = other . The base group is ùë¶ 0 . * * * , * * , and * denote significance at 1 % , 5 % , and 10 % , respectively . Model 2 includes a set of independent variables of interest and indicates that a start - up that has greater number of products ( preclinical ) has a significantly greater regression coefficient in ùë¶ 3 , at the conventional levels , followed by ùë¶ 2 , ùë¶ 1 , and ùë¶ 4 in order . In other words , a start - up that has more products being developed in the preclinical stage tends to finance its projects from CVCs , most likely , followed by IVCs , angels , and syndicated investors in order . The regression coefficients of number of products ( phase I ) are greatest in ùë¶ 2 followed by ùë¶ 3 , ùë¶ 1 , and ùë¶ 4 in order . These results suggest that a start - up that has more products in phase I is more likely to finance its projects from IVCs followed by CVCs , angels , and syndicated investors in order . This pattern is similar with that shown with number of products ( preclinical ) except that IVCs and CVCs are replaced with each other . Hence , these results are consistent with my predictions made in hypotheses 2 and 3 that a start - up is more likely to finance its projects from CVCs and IVCs in early stages . However , these results do not support hypothesis 1 . This inconsistency occurs possibly , as noted , due to the nature of industry where a greater amount of product development costs is required and this amount is often beyond the range angels can provide . There is an obviously distinguishable pattern with number of products ( phase II ) . The regression coefficients of number of products ( phase II ) is great in ùë¶ 4 followed by ùë¶ 3 , ùë¶ 1 , and ùë¶ 2 . This transition of orders continues with number of products ( phase III ) except that ùë¶ 1 and ùë¶ 2 are replaced with each other . These results suggest that a start - up that has more products in later stages tends to finance its projects from syndicated investors and solely CVCs , supporting hypotheses 2 and 3 . Number of products ( launched ) indicates a similar pattern of that of number of products ( preclinical ) in which a start - up tends to finance its projects from solely either one of IVCs or CVCs . This pattern suggests that a start - up that has launched a product regresses toward its financing pattern in the early stage of product development process . Combined together , this setting collectively provides systematic evidence to support hypotheses 2 and 3 . However , it doesn ‚Äô t support hypothesis 1 . For a better visualization , the ranks of regression coefficients across ùë¶ ùëñ along the product development stages are provided in Table 3 . In Panel A , ùë¶ 3 is most likely to finance a start - up that has a greater number of product in the preclinical stage followed by ùë¶ 2 , ùë¶ 1 , and ùë¶ 4 . As noted , this pattern is similar with that with number of products ( phase I ) . With number of products ( phase II ) ùë¶ 4 is most likely to finance a start - up that develops a great number of products in phase II followed by ùë¶ 3 , ùë¶ 2 , and ùë¶ 1 . This pattern continues with number of products ( phase III ) . Table 3 : Post estimation of multinomial logit regressions . Panel A Ranking of financing sources by regression coefficients ùë¶ ùëñ ùë¶ 1 ùë¶ 2 ùë¶ 3 ùë¶ 4 Number of products ( preclinical ) 3 2 1 4 Number of products ( phase I ) 3 1 2 4 Number of products ( phase II ) 3 4 2 1 Number of products ( phase III ) 3 4 2 1 Number of products ( launched ) 3 1 2 4 Panel B . Tests of number of products Financing sources œá 2 Prob \ gt œá 2 Number of products ( preclinical ) 7 . 88 * 0 . 09 Number of products ( phase I ) 8 . 20 * 0 . 08 Number of products ( phase II ) 8 . 03 * 0 . 09 Number of products ( phase III ) 9 . 90 * * 0 . 04 Number of products ( launched ) 2 . 81 0 . 59 * * * , * * , and * denote significance at 1 % , 5 % , and 10 % , respectively . Table 4 : Financing source and ratio of products within R & D stages . Fixed effects multinomial logit regression Model ( 1 ) ( 2 ) ùë¶ ùëñ 1 2 3 4 1 2 3 4 Ratio of products ( preclinical ) 0 . 350 1 . 074 2 . 093 * * * ‚àí 59 . 221 ( 0 . 526 ) ( 0 . 680 ) ( 0 . 486 ) ( 4376 . 328 ) Ratio of products ( phase I ) ‚àí 0 . 539 1 . 336 1 . 301 ‚àí 0 . 272 ( 1 . 572 ) ( 1 . 788 ) ( 1 . 365 ) ( 4 . 816 ) 12 A u t o m a t i c a ll y g e n e r a t e d r o u g hP D F b y P r oo f C h e c k f r o m R i v e r V a ll e y T e c h n o l o g i e s L t d DEGRUYTER Kang Ratio of products ( phase II ) 0 . 392 0 . 446 2 . 271 * 4 . 296 ( 1 . 303 ) ( 2 . 100 ) ( 1 . 207 ) ( 3 . 665 ) Ratio of products ( phase III ) 0 . 292 0 . 538 4 . 591 * * 4 . 590 ( 2 . 017 ) ( 2 . 935 ) ( 1 . 814 ) ( 3 . 158 ) Ratio of products ( launched ) 1 . 702 ‚àí 0 . 319 3 . 189 ‚àí 81 . 290 ( 2 . 764 ) ( 5 . 218 ) ( 2 . 354 ) ( 3 . 4e + 04 ) Age 0 . 086 * * * ‚àí 0 . 051 ‚àí 0 . 116 * * * 0 . 083 0 . 087 * * * ‚àí 0 . 051 ‚àí 0 . 131 * * * 0 . 013 ( 0 . 027 ) ( 0 . 059 ) ( 0 . 033 ) ( 0 . 143 ) ( 0 . 027 ) ( 0 . 060 ) ( 0 . 035 ) ( 0 . 159 ) Patents 0 . 001 0 . 014 * * 0 . 009 * * * ‚àí 0 . 043 0 . 001 0 . 013 * * 0 . 006 * ‚àí 0 . 041 ( 0 . 003 ) ( 0 . 006 ) ( 0 . 003 ) ( 0 . 046 ) ( 0 . 003 ) ( 0 . 006 ) ( 0 . 003 ) ( 0 . 041 ) Forward citations 0 . 000 ‚àí 0 . 002 * * 0 . 001 0 . 001 0 . 000 ‚àí 0 . 002 * * 0 . 001 * 0 . 001 ( 0 . 000 ) ( 0 . 001 ) ( 0 . 000 ) ( 0 . 003 ) ( 0 . 000 ) ( 0 . 001 ) ( 0 . 000 ) ( 0 . 003 ) Backward citations ‚àí 0 . 000 0 . 001 ‚àí 0 . 001 * * * ‚àí 0 . 001 ‚àí 0 . 000 0 . 001 ‚àí 0 . 001 * * * ‚àí 0 . 000 ( 0 . 000 ) ( 0 . 001 ) ( 0 . 000 ) ( 0 . 003 ) ( 0 . 000 ) ( 0 . 001 ) ( 0 . 000 ) ( 0 . 003 ) External R & D 0 . 002 ‚àí 0 . 012 0 . 018 * * * 0 . 021 0 . 001 ‚àí 0 . 016 0 . 015 * * 0 . 045 ( 0 . 006 ) ( 0 . 014 ) ( 0 . 007 ) ( 0 . 036 ) ( 0 . 006 ) ( 0 . 015 ) ( 0 . 007 ) ( 0 . 036 ) Funding amount ‚àí 0 . 668 * * * ‚àí 0 . 153 ‚àí 1 . 232 * * * 0 . 292 ‚àí 0 . 657 * * * ‚àí 0 . 115 ‚àí 1 . 156 * * * 0 . 204 ( 0 . 095 ) ( 0 . 170 ) ( 0 . 110 ) ( 0 . 444 ) ( 0 . 095 ) ( 0 . 173 ) ( 0 . 113 ) ( 0 . 442 ) Cumulative funding amount 0 . 633 * * * ‚àí 0 . 893 * * * 0 . 527 * * * ‚àí 2 . 089 * * * 0 . 624 * * * ‚àí 0 . 937 * * * 0 . 346 * * ‚àí 2 . 085 * * * ( 0 . 117 ) ( 0 . 269 ) ( 0 . 160 ) ( 0 . 629 ) ( 0 . 118 ) ( 0 . 275 ) ( 0 . 169 ) ( 0 . 668 ) Financing experience ‚àí 0 . 006 ‚àí 0 . 064 ‚àí 0 . 036 ‚àí 0 . 294 ‚àí 0 . 004 ‚àí 0 . 059 ‚àí 0 . 003 ‚àí 0 . 273 ( 0 . 037 ) ( 0 . 081 ) ( 0 . 046 ) ( 0 . 238 ) ( 0 . 037 ) ( 0 . 082 ) ( 0 . 048 ) ( 0 . 258 ) Prior IVC ‚àí 0 . 632 * * * 22 . 838 ‚àí 0 . 300 20 . 629 ‚àí 0 . 641 * * * 22 . 863 ‚àí 0 . 368 * 20 . 475 ( 0 . 195 ) ( 598 . 305 ) ( 0 . 209 ) ( 1157 . 055 ) ( 0 . 196 ) ( 599 . 215 ) ( 0 . 219 ) ( 1063 . 792 ) Prior CVC ‚àí 0 . 189 ‚àí 0 . 602 * 20 . 136 19 . 499 ‚àí 0 . 193 ‚àí 0 . 592 * 20 . 277 19 . 539 ( 0 . 241 ) ( 0 . 316 ) ( 805 . 384 ) ( 1728 . 834 ) ( 0 . 241 ) ( 0 . 317 ) ( 782 . 546 ) ( 1619 . 759 ) Constant ‚àí 1 . 771 * * * ‚àí 18 . 128 ‚àí 18 . 501 ‚àí 33 . 736 ‚àí 1 . 779 * * * ‚àí 18 . 162 ‚àí 18 . 453 ‚àí 33 . 460 ( 0 . 197 ) ( 598 . 304 ) ( 805 . 384 ) ( 2080 . 297 ) ( 0 . 198 ) ( 599 . 214 ) ( 782 . 546 ) ( 1937 . 850 ) Firm fixed effects Yes Yes Yes Yes Yes Yes Yes Yes Year fixed effects Yes Yes Yes Yes Yes Yes Yes Yes N 1306 1306 Log likelihood ‚àí 1 . 1e + 03 ‚àí 1 . 1e + 03 Prob \ gt œá 2 0 . 000 0 . 000 pseudo R 2 0 . 373 0 . 393 Notes : ùë¶ ùëñ includes ùë¶ 1 = angel , ùë¶ 2 = IVC , ùë¶ 3 = CVC , ùë¶ 4 = syndication , and ùë¶ 0 = other . The base group is ùë¶ 0 . * * * , * * , and * denote significance at 1 % , 5 % , and 10 % , respectively . Table 5 : FDA approval process . Stages Preclinical Phase I Phase II Phase III Activities Target and lead identification ; testing in vitro and in vivo ( animal model ) Tests in healthy volunteers Efficacy and safety in patients ; dose selection Registration studies to establish safety and efficacy Duration Years Months Less than 1 year About 2 years Cost Millions of US dollars Millions of US dollars At least tens of millions of US dollars Often hundreds of millions of US dollars Source : Miemietz ( 2013 ) . For a corollary analysis , Wald tests are used to test a null hypothesis , ùêª 0 : ùõΩùë¶ 1 = ùõΩùë¶ 2 = ùõΩùë¶ 3 = ùõΩùë¶ 4 = 0 , hypothe - sized that parameters estimated in the regressions are all zero in the population . The Wald test assesses ùêª 0 by considering two pieces of information ( Long and Freese 2003 ) . First , all else being equal , the greater the dis - tance between the estimated coefficients and the hypothesized values , the less support I have for ùêª 0 . Second , the greater the curvature of the log - likelihood function , the more certainty I have about my estimates . This means that smaller differences between the estimates and hypothesized values are required to reject ùêª 0 . The test results are presented in Panel B and indicate that number of products ( preclinical ) , number of products ( phase I ) , and number of products ( phase II ) reject ùêª 0 at the 10 % level ; and number of products ( phase III ) does at 5 % level . Using the alternative set of independent variables , I examine the issue of the unit of analysis in Table 4 . As noted , a set of ratio variables include ratio of products ( preclinical ) , ratio of products ( phase I ) , ratio of products ( phase 13 A u t o m a t i c a ll y g e n e r a t e d r o u g hP D F b y P r oo f C h e c k f r o m R i v e r V a ll e y T e c h n o l o g i e s L t d Kang DEGRUYTER II ) , ratio of products ( phase III ) , and ratio of products ( launched ) , and is used in the same specification presented in Table 3 . Model 1 includes control variables . In Model 2 , a new set of variable indicate overall consistent patterns of regression coefficients with those presented in Table 3 . Ratio of products ( preclinical ) indicates an exactly same order of financing sources as that of Table 3 . Ratio of products ( phase I ) presents the same order of the first two financing sources , including ùë¶ 2 and ùë¶ 3 , but ùë¶ 1 and ùë¶ 4 are replaced with each other . Ratio of products ( phase II ) presents a consistent order with that in Table 3 . With ratio of products ( phase III ) the first two financing sources are replaced with each other and so the last two financing sources are , resulting ùë¶ 3 , ùë¶ 4 , ùë¶ 2 , and ùë¶ 1 in order . Combined together , my benchmark findings are robust and alleviates a concern about varying size independent variables . 5 Discussion and Limitations In this study , I aimed to examine how a start - up ‚Äô s product development stages and its financing sources are interacted with each other . With several hypotheses that are elicited based on the dynamics of a start - up ‚Äô s life cycle , this study is premised that a start - up needs a different set of resources along with its life cycle and finances its projects depending on its product development stages to procure these resources . In the setting of biopharmaceutical industry , I find systematic evidence that a start - up that has more products being developed in early stages , including preclinical stage and phase I , tends to finance its projects from solely either one of IVCs or CVCs . More specifically , CVCs are more preferred in preclinical stage and IVCs are in phase I . This set of preferences might be determined by the necessary resources that each type of investors can provide for a start - up in an efficient manner . As a start - up ‚Äô s products become more matured and get into later stages , including phase II and phase III , a start - up tends to finance its projects from CVC solely or syndicated investors combining CVCs and IVCs . This transition of financing sources can be occurred because a start - up can access a better pool of investors with reduced uncertainty due to its technological advancements . 5 . 1 Implications in the Biopharmaceutical Industry The biopharmaceutical industry is uniquely characterized by the complexity and length of the product de - velopment cycle and thus an individual firm performance is determined by foremost the products within its R & D pipeline . Given this uniqueness , it is a serious concern that this industry has been suffering from a de - crease of R & D productivity over the past two decades . The decrease of R & D productivity makes down - stream co - specialized assets to be under - utilized for a small range of therapeutic research that has been traditionally focused in the industry . As noted , biotechnology - based start - ups help fill these gaps along the R & D pipeline by providing a new scientific way to cure the focal disease . As a result , pharmaceutical giant companies often become a hub to gather external technologies and commercialize promising products being developed by the biotechnology - based start - ups . By exploring how the entrepreneurial finance market fulfills necessary complementary assets for biotech - nology start - ups in a timely manner , this study provides an alternative way to balance between the attraction of investments in R & D and the price of drugs , which is pursued by the U . S . government . The new administration of Trump government desperately seeks an effective way to reduce drug prices by speeding up the process of bringing new drugs to market and removing regulations ( Newsweek 2017 ) . The rationale is that easing FDA requirement would save several years and millions of dollars off a pharmaceutical company ‚Äô s investment in experimental products . This plan raises concerns from healthcare industry experts immediately because they believe that the market price does not depend on the up - front investment and the government lacks the means to force drug companies to lower prices in parallel with reduced development costs . Moreover , testing new drugs for safety only ( e . g . , what it done in phase I ) and not benefit ( e . g . , what it done in phase II and phase III ) could accomplish the opposite goal and lead to spending more for therapies that have no great outcome . By highlighting an effective financing arrangement to enhance a start - up ‚Äô s R & D pipeline , this study provides an alternative approach to reduce drug prices . This study suggests that a start - up can facilitate its R & D process by fulfilling necessary resources from different types of investors in a timely manner . This positive flow of resources may allow a start - up to reduce technological uncertainties and develop more products in its R & D pipeline . Consequently , more products will appear in the market along with existing drugs that are still ef - fective but inferior to these new products . The competition between these new and existing drugs may generate price discrimination effects in which affordable drugs and high - end quality drugs with higher prices co - exist in the market . This competition effect may pull the drug prices down eventually . Given this set of consequences , the role of government should focus on facilitating a start - up ‚Äô s R & D pipeline and , more specifically , formulate policy ( e . g . , tax policy to attract each type of investors by a start - up ‚Äô s R & D stages accordingly ) to create a better flow of resources for a start - up . 14 A u t o m a t i c a ll y g e n e r a t e d r o u g hP D F b y P r oo f C h e c k f r o m R i v e r V a ll e y T e c h n o l o g i e s L t d DEGRUYTER Kang 5 . 2 Limitations The limitation of this study provides avenues for future research . The scope of this study is limited within the biopharmaceutical industry . To the extent that each industry has its own technological and managerial contexts , the results of this study should be interpreted with caution especially when they are applied in the contexts of other high - tech industries . As noted , a biopharmaceutical start - up often takes a much longer time and greater resources in the product development process than any other high - tech start - ups . Hence , the role of complementary assets provided by investors can be more salient compared with that in other industries . Furthermore , the FDA passes a new product to the market only when this product is proved to be more effective than existing drugs ( e . g . , what it done in phase II and phase III ) . This is also comparable with other high - tech industries that various qualities of products would be marketable without the intervention of government . Moreover , the scope of this study does not include public and indirect financing sources that have their own goals and investment patterns . For example , public financing sources , including governmental research grants and other research grants provided by universities , leading labs , and hospitals , often seek basic studies that focus on ‚Äú R ‚Äù ( research ) rather than ‚Äú D ‚Äù ( development ) . This investment pattern may generate a quite dif - ferent consequences from that of private financing activities . Future studies need to fill this gap . In addition , the heterogeneity within investor groups is not considered in this study . For example , investor characteristics , including reputations and experiences , matter to make financing decisions for start - ups . The exclusion of this analysis is mainly because this study focuses on comparisons across investor groups . Given this purpose of study , the heterogeneity within investor groups cannot simply compare across investor groups . Finally , future studies need to utilize more various data sources to refine the results of this study . While this study utilized the ReCap database , there are some other available data sources , including Securities Data Com - pany ( SDC ) , Merit - Cati , Core , and Bioscan databases . Each data source has its advantages and disadvantages that would be suited to specific research topics ( Schilling 2009 ) and no database is fully complete . This occurs because start - ups are not required to report all the funding and alliance activities to any governing body . As a result , the coverage of data sources is not highly consistent and it is impractical to combine all the data sources in a single study due to the prohibitive costs . It is still worthy that future studies examine the consistencies of several dimensions of a start - up ‚Äô s financing and alliance activities across several databases . Appendix A Variable descriptions Variable Description Data source Financing source ( ùë¶ ùëñ ) A discrete variable that equals one if a start - up finances through angels ( ùë¶ ùëñ = 1 ) , two if it does through IVCs ( ùë¶ ùëñ = 2 ) , three if it does through CVCs ( ùë¶ ùëñ = 3 ) , and four if it does through syndicated investments between IVCs and CVCs . If a start - up finances through other investors , including founders , research laps , schools , and governments , it is coded as ùë¶ ùëñ = 0 and used as a base group in the following analyses . Deloitte Recap Number of products The number of products within a start - up ‚Äô s R & D pipeline . This variable is divided into five stages , including preclinical , phase I , phase II , phase III , and launched stages . For example , number of products ( preclinical ) is the number of products in the preclinical stage , and the other categories are as follows . Each stage is used as an independent variable in the following analyses . PharmaProject Ratio of products The ratio of product in each stage to the total number of products plus one within a start - up ‚Äô s R & D pipeline . Similar with number of products , this variable is divided into five stages , including preclinical , phase I , phase II , phase III , and launched stages . For example , number of products ( preclinical ) is calculated as number of products ( preclinical ) divided by the total number of products within a start - up ‚Äô s R & D pipeline ( i . e . , all the five stages ) plus one . The other categories are as follows . Each stage is used as an independent variable in the following analyses . PharmaProject Age Number of days from a start - up ‚Äô s founding to financing , divided by 365 Deloitte Recap 15 A u t o m a t i c a ll y g e n e r a t e d r o u g hP D F b y P r oo f C h e c k f r o m R i v e r V a ll e y T e c h n o l o g i e s L t d Kang DEGRUYTER Patents Number of patents applied by a start - up in a year U . S . Patent Office Forward citations Number of forward citations ( i . e . , number of patents citing a start - up ‚Äô s patents ) in a year U . S . Patent Office Backward citations Number of backward citations ( i . e . , number of patents cited by a start - up ‚Äô s patents ) in a year U . S . Patent Office External R & D Stock of technological alliances , including collaborative research alliances , licensing contracts , and other types of research agreements , in a year Deloitte Recap Funding amount The log of amount of financing in million U . S . dollars Deloitte Recap Cumulative funding amount The log of cumulative amount of financing in million U . S . dollars Deloitte Recap Financing experience Number of prior fundraising activities Deloitte Recap Prior IVC An indicator variable that equals one if a start - up has previously financed through IVCs , and zero otherwise Deloitte Recap Prior CVC An indicator variable that equals one if a start - up has previously financed through CVCs , and zero otherwise Deloitte Recap B Major CVCs and IVCs included in the Deloitte Recap database CVC Number of investments Amount of investments IVC Number of investments Amount of investments Eli Lilly 36 387 . 24 Domain 44 477 . 82 Genetech 26 173 . 27 NEA 33 512 . 63 Elan 26 157 . 12 H & Q 32 174 . 89 Pfizer 25 184 . 66 KPCB 32 170 . 73 SmithKline 24 155 . 41 Venture Investors 29 337 . 10 Warner - Lambert 19 66 . 09 UKN 26 87 . 92 Abbott 17 491 . 55 Alta 25 255 . 11 Ciba - Geigy 17 102 . 75 IVP 25 186 . 22 Genzyme 16 129 . 10 Mayfield 25 150 . 09 Novartis 15 306 . 42 HCV 22 93 . 20 Total 221 2153 . 61 Total 293 2445 . 71 ( Mean ) ( 22 . 1 ) ( 215 . 36 ) ( Mean ) ( 29 . 30 ) ( 244 . 57 ) Note : These figures use all the observations from the Deloitte Recap database . The amount of investments is in million U . S . dollars . C Sample distribution over time 16 A u t o m a t i c a ll y g e n e r a t e d r o u g hP D F b y P r oo f C h e c k f r o m R i v e r V a ll e y T e c h n o l o g i e s L t d DEGRUYTER Kang Note : This figure illustrates the yearly information of angels , IVCs , CVCs , and syndicated between IVC and CVC invest - ments included in the database . This figure is important because it allows me to investigate whether or not IVC and CVC financing sources have been available to a start - up over time . If either IVCs or CVCs were extremely scarce during a par - ticular period and not readily available , a start - up ‚Äô s financing choice would be heavily impacted by the availability of each financing source rather than the stages of R & D pipelines I study . If this concern is not the case , I should see a notable pat - tern in which the sample distributions of financing sources move together over time . This figure indicates that the num - ber of samples in financing sources gradually increased together in the 1990s , peaked in the early 2000s , and gradually decreased afterward . D Correlation tables 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 1 1 . 00 2 0 . 09 1 . 00 3 0 . 08 0 . 54 1 . 00 4 0 . 08 0 . 58 0 . 48 1 . 00 5 0 . 08 0 . 42 0 . 51 0 . 36 1 . 00 6 0 . 05 0 . 17 0 . 25 0 . 13 0 . 21 1 . 00 7 0 . 12 0 . 78 0 . 39 0 . 39 0 . 32 0 . 09 1 . 00 8 0 . 08 0 . 26 0 . 68 0 . 30 0 . 31 0 . 09 0 . 25 1 . 00 9 0 . 09 0 . 23 0 . 26 0 . 71 0 . 18 0 . 05 0 . 21 0 . 24 1 . 00 10 0 . 07 0 . 13 0 . 19 0 . 13 0 . 68 0 . 04 0 . 14 0 . 17 0 . 10 1 . 00 11 0 . 03 0 . 02 0 . 03 0 . 02 0 . 03 0 . 79 0 . 02 0 . 01 0 . 01 0 . 00 1 . 00 12 ‚àí 0 . 06 0 . 07 0 . 07 0 . 08 0 . 07 0 . 03 0 . 07 0 . 05 0 . 05 0 . 05 0 . 02 1 . 00 13 0 . 04 0 . 15 0 . 10 0 . 16 0 . 12 0 . 02 0 . 10 0 . 05 0 . 05 0 . 03 0 . 00 0 . 24 1 . 00 14 ‚àí 0 . 02 0 . 06 0 . 06 0 . 08 0 . 08 0 . 00 0 . 03 0 . 03 0 . 03 0 . 02 0 . 01 0 . 22 0 . 68 1 . 00 15 ‚àí 0 . 04 0 . 08 0 . 08 0 . 12 0 . 12 0 . 00 0 . 05 0 . 05 0 . 06 0 . 05 0 . 00 0 . 22 0 . 61 0 . 69 1 . 00 16 ‚àí 0 . 02 0 . 21 0 . 19 0 . 17 0 . 14 0 . 11 0 . 16 0 . 08 0 . 07 0 . 05 0 . 04 0 . 52 0 . 25 0 . 16 0 . 15 1 . 00 17 ‚àí 0 . 04 0 . 08 0 . 04 0 . 06 0 . 05 0 . 01 0 . 06 0 . 03 0 . 04 0 . 03 0 . 01 0 . 33 0 . 17 0 . 14 0 . 15 0 . 31 1 . 00 18 0 . 06 0 . 13 0 . 10 0 . 11 0 . 09 0 . 04 0 . 13 0 . 08 0 . 07 0 . 06 0 . 03 0 . 66 0 . 25 0 . 24 0 . 25 0 . 52 0 . 73 1 . 00 19 ‚àí 0 . 01 0 . 13 0 . 13 0 . 13 0 . 11 0 . 05 0 . 11 0 . 09 0 . 08 0 . 06 0 . 03 0 . 76 0 . 26 0 . 27 0 . 28 0 . 57 0 . 42 0 . 78 1 . 00 20 0 . 26 0 . 03 0 . 01 0 . 03 ‚àí 0 . 01 0 . 02 0 . 03 0 . 02 0 . 02 ‚àí 0 . 01 0 . 02 0 . 11 0 . 13 0 . 14 0 . 12 0 . 12 0 . 30 0 . 42 0 . 30 1 . 00 21 0 . 30 0 . 10 0 . 09 0 . 08 0 . 08 0 . 04 0 . 11 0 . 07 0 . 07 0 . 06 0 . 03 0 . 41 0 . 15 0 . 13 0 . 09 0 . 32 0 . 32 0 . 55 0 . 53 0 . 18 1 . 00 Note : Variables include 1 . Financing source ( ùë¶ ùëñ ) ; 2 . Number of products ( preclinical ) ; 3 . Number of products ( phase I ) ; 4 . Number of products ( phase II ) ; 5 . Number of products ( phase III ) ; 6 . Number of products ( launched ) ; 7 . Ratio of products ( preclinical ) ; 8 . Ratio of products ( phase I ) ; 9 . Ratio of products ( phase II ) ; 10 . Ratio of products ( phase III ) ; 11 . Ratio of products ( launched ) ; 12 . Age ; 13 . Patents ; 14 . Forward citations ; 15 . Backward citations ; 16 . External R & D ; 17 . Funding amount ; 18 . Cumulative funding amount ; 19 . Financing experience ; 20 . Prior IVC ; and 21 . Prior CVC . Notes 1 There are also several public financing sources . For example , the National Institutes of Health operates the NIH SBIR / STTR Award program to fund life science research - based firms in early stages . However , the amount granted in these programs , totaling $ 0 . 6 billion in 2013 , is incomparable with that of private financing sources , totaling more than $ 10 billion , invested in the biopharmaceutical industry ( https : / / sbir . nih . gov ; PricewaterhouseCoopers 2014 ) . Moreover , the objectives and patterns of investments are different across public and private funding sources . As a result , this study focuses on private entrepreneurial funding sources . 2 Phase I is human pharmacology and requires small trials , recruiting up to about 30 patients . Phase II is therapeutic exploratory ; and it expands trials to patients who have the same type of disease to find out the extent of side - effects , and appropriate usage of drugs . Phase III is therapeutic confirmatory ; and it compares new drugs with the best currently available drugs or treatments and releases them if they pass . 3 The monitoring service represents activities that IVCs serve on oversight role by using the due diligence process and the vote rights in the board of directors ( Kaplan and Str√∂mberg 2001 ) . The professionalization service includes developing a business plan , facilitating strategic partnerships , and developing new businesses . The certification effect helps a start - up raise addition funds by signaling the quality of start - up to the market ( Hsu and Ziedonis 2013 ; Megginson and Weiss 1990 ) . References Adamati , A . R . , andP . Pfleiderer . 1994 . ‚Äú RobustFinancialContractingandtheRoleofVentureCapitalists . ‚Äù JournalofFinance 49 ( 2 ) : 371 ‚Äì 402 . 17 A u t o m a t i c a ll y g e n e r a t e d r o u g hP D F b y P r oo f C h e c k f r o m R i v e r V a ll e y T e c h n o l o g i e s L t d Kang DEGRUYTER Alvarez - Garrido , E . , andG . Dushnitsky . 2015 . ‚Äú AreEntrepreneurialVenture ‚Äô sInnovationRatesSensitivetoInvestorComplementaryAssets ? ComparingBiotechVenturesBackedbyCorporateandIndependentVCs . ‚Äù StrategicManagementJournal 37 ( 5 ) : 819 ‚Äì 834 . Amit , R . , J . A . Brander , andC . Zott . 1998 . ‚Äú WhyDoVentureCapitalFirmsExist ? TheoryandCanadianEvidence . ‚Äù JournalofBusinessVenturing 13 : 441 ‚Äì 466 . Basu , S . , C . Phelps , andS . Kotha . 2011 . ‚Äú TowardsUnderstandingWhoMakesCorporateVentureCapitalInvestmentsandWhy . ‚Äù Journalof BusinessVenturing 26 ( 2 ) : 153 ‚Äì 171 . Baum , J . A . , andB . S . Silverman . 2004 . ‚Äú PickingWinnersorBuildingThem ? Alliance , Intellectual , andHumanCapitalasSelectionCriteriain VentureFinancingandPerformanceofBiotechnologyStart - Ups . ‚Äù JournalofBusinessVenturing 19 : 411 ‚Äì 436 . Benson , D . , andR . H . Ziedonis . 2010 . ‚Äú CorporateVentureCapitalandtheReturnstoAcquiringPortfolioCompanies . ‚Äù JournalofFinancialEco - nomics 98 ( 3 ) : 478 ‚Äì 499 . Bertoni , F . , M . Colombo , andL . Grilli . 2013 . ‚Äú VentureCapitalInvestorTypeandtheGrowthModeofNewTechnology - BasedFirms . ‚Äù Small BusinessEconomics 40 ( 3 ) : 527 ‚Äì 552 . Bhak , B . H . , andM . Gort . 1993 . ‚Äú DecomposingLearningbyDoinginNewPlants . ‚Äù JournalofPoliticalEconomy 101 : 561 ‚Äì 583 . Burt , R . S . 1983 . CorporateProfitsandCooptation : NetworksofMarketConstraintsandDirectorateTiesintheAmericanEconomy . NewYork : Academic Press . Bygrave , W . D . 1987 . ‚Äú SyndicatedInvestmentsbyVentureCapitalFirms : ANetworkingPerspective . ‚Äù JournalBusinessVenturing 2 ( 2 ) : 139 ‚Äì 154 . Casciaro , T . , andM . J . Piskorski . 2005 . ‚Äú PowerImbalance , MutualDependence , andConstraintAbsorption : ACloserLookatResourceDepen - denceTheory . ‚Äù AdministrativeScienceQuarterly 50 : 167 ‚Äì 199 . Ceccagnoli , M . , M . J . Higgins , andH . D . Kang . 2014 . Corporateventurecapitalasarealoptioninthemarketsfortechnology . Workingpaper , GeorgiaInstituteofTechnology Chemmanur , T . J . , andZ . Chen . 2014 . ‚Äú VentureCapitalistsversusAngels : TheDynamicsofPrivateFirmFinancingContracts . ‚Äù ReviewsofCorpo - rateFinanceStudies 3 ( 1 ‚Äì 2 ) : 39 ‚Äì 86 . Cohen , W . M . , R . Nelson , andJ . Walsh . 2000 . Protectingtheirintellectualassets : AppropriabilityconditionsandwhyU . S . manufacturingfirms patent ( ornot ) . NBERWorkingPaper # 7522 . Cooley , T . F . , andB . D . Smith . 1998 . ‚Äú FinancialMarkets , Specialization , andLearningbyDoing . ‚Äù ResearchinEconomics 52 ( 4 ) : 333 ‚Äì 361 . Denis , D . J . 2004 . ‚Äú EntrepreneurialFinance : AnOverviewoftheIssuesandEvidence . ‚Äù JournalofCorporateFinance 10 : 301 ‚Äì 326 . Dushnitsky , G . , andM . J . Lenox . 2005 . ‚Äú WhenDoIncumbentsLearnfromEntrepreneurialVentures ? CorporateVentureCapitalandInvesting FirmInnovationRates . ‚Äù ResearcherPolicy 34 ( 5 ) : 615 ‚Äì 639 . Dushnitsky , G . , andM . J . Lenox . 2006 . ‚Äú WhenDoesCorporateVentureCapitalInvestmentCreateFirmValue ? ‚Äù JournalofBusinessVenturing 21 : 753 ‚Äì 772 . Dushnitsky , G . , andZ . Shapira . 2010 . ‚Äú EntrepreneurialFinanceMeetsOrganizationalReality : ComparingInvestmentPracticesandPerfor - manceofCorporateandIndependentVentureCapitalists . ‚Äù StrategicManagementJournal 31 ( 9 ) : 990 ‚Äì 1017 . Dushnitsky , G . , andJ . M . Shaver . 2009 . ‚Äú LimitationstoInterorganizationalKnowledgeAcquisition : TheParadoxofCorporateVentureCapi - tal . ‚Äù StrategicManagementJournal 30 ( 10 ) : 1045 ‚Äì 1064 . Dutta , S . , andT . Folta . 2016 . ‚Äú AComparisonofAngelandVentureCapitalistsonInnovationandValueCreation . ‚Äù JournalofBusinessVenturing 31 ( 1 ) : 39 ‚Äì 58 . Dyer , J . H . , andH . Singh . 1998 . ‚Äú TheRelationalView : CooperativeStrategyandSourcesofInterorganizationalCompetitiveAdvantage . ‚Äù AcademyofManagementReview 23 : 660 ‚Äì 679 . Freear , J . , J . Sohl , andW . E . Wetzel . 1995 . ‚Äú Angels : PersonalInvestorsintheVentureCapitalMarket . ‚Äù EntrepreneurshipRegionalDevelopment 7 : 85 ‚Äì 94 . Freear , J . , J . Sohl , andW . E . Wetzel . 1996 . Creatingnewcapitalmarketsforemergingventures . Workingpaper , UniversityofNewHampshire . Fulghieri , P . , andM . Sevilir . 2009 . ‚Äú OrganizationandFinancingofInnovation , andtheChoicebetweenCorporateandIndependentVenture Capital . ‚Äù JournalofFinancialQuantitativeAnalysis 44 ( 6 ) : 1291 ‚Äì 1321 . Gans , J . S . , D . H . Hsu , andS . Stern . 2002 . ‚Äú WhenDoesStart - UpInnovationSpurtheGaleofCreativeDestruction ? ‚Äù RANDJournalofEconomics 33 : 571 ‚Äì 586 . Gompers , P . A . 1995 . ‚Äú OptimalInvestment , Monitoring , andtheStagingofVentureCapital . ‚Äù JournalofFinance 50 ( 5 ) : 1461 ‚Äì 1489 . Gompers , P . A . 2002 . ‚Äú CorporationsandtheFinancingofInnovation : TheCorporateVenturingExperience . ‚Äù FederalReserveBankofAtlanta EconomReviews 87 ( 4 ) : 1 ‚Äì 18 . Gompers , P . A . , andJ . Lerner . 2000a . ‚Äú TheDeterminantsofCorporateVentureCapitalSuccess : OrganizationalStructure , IncentivesandCom - plementarities . ‚Äù In ConcentratedCorporateOwnership , edR . Morck . Chicago : UniversityofChicagoPress . Grabowski , H . G . , andM . Kyle . 2008 . MergersandAlliancesinPharmaceutical : EffectsonInnovationandR & DProductivity . TheEconomicsofCorporate GovernanceandMergers , 262 ‚Äì 287 . Cheltenham : EdwardElgar . Greene , W . H . 1993 . EconometricAnalysis , 5thed . NewJersey : PrenticeHall . Griffin , A . 2002 . ‚Äú ProductDevelopmentCycleTimeforBusiness - To - BusinessProducts . ‚Äù IndustrialMarketingManagement 31 : 291 ‚Äì 304 . Guo , B . , Y . Lou , andD . Perez - Castrillo . 2011 . Investment , duration , andexitstrategiesforcorporateandindependentventurecapitalbacked startups . Workingpaper , UniversidadCarlosIIIdeMadrid . Hall , B . , A . Jaffe , andM . Trajtenberg . 2005 . ‚Äú MarketValueandPatentCitations . ‚Äù RANDJournalofEconomics 36 ( 1 ) : 16 ‚Äì 38 . Hellmann , T . F . 2002 . ‚Äú ATheoryofStrategicInvesting . ‚Äù JournalofFinancialEconomics 64 ( 2 ) : 285 ‚Äì 314 . Hellmann , T . F . , andV . Thiele . 2015 . ‚Äú FriendsorFoes ? theInterrelationshipbetweenAngelandVentureCapitalMarkets . ‚Äù JournalofFinancial Economics 115 ( 3 ) : 639 ‚Äì 653 . Hsu , D . H . 2004 . ‚Äú WhatDoEntrepreneursPayforVentureCapitalAffiliation ? ‚Äù JournalofFinance 59 ( 4 ) : 1805 ‚Äì 1844 . Hsu , D . H . , andR . Ziedonis . 2013 . ‚Äú ResourcesasDualSourcesofAdvantage : ImplicationsforValuingEntrepreneurial - FirmPatents . ‚Äù Strategic ManagementJournal 34 ( 7 ) : 761 ‚Äì 781 . Iansiti , M . 1995 . ‚Äú TechnologyIntegration : ManagingTechnologicalEvolutioninaComplexEnvironment . ‚Äù ResearcherPolicy 24 : 521 ‚Äì 542 . Jensen , M . 1993 . ‚Äú TheModernIndustrialRevolution , Exit , andtheFailureofInternalControlSystems . ‚Äù JournalofFinance 48 : 831 ‚Äì 880 . 18 A u t o m a t i c a ll y g e n e r a t e d r o u g hP D F b y P r oo f C h e c k f r o m R i v e r V a ll e y T e c h n o l o g i e s L t d DEGRUYTER Kang Kaplan , S . , andP . Str√∂mberg . 2001 . ‚Äú VentureCapitalistsasPrincipals : Contracting , Screening , andMonitoring . ‚Äù TheAmericanEconomicReview 91 : 426 ‚Äì 430 . Katila , R . , J . D . Rosenberger , andK . M . Eisenhardt . 2008 . ‚Äú SwimmingwithSharks : TechnologyVentures , DefenseMechanismsandCorporate Relationships . ‚Äù AdministrativeScienceQuarterly 53 ( 2 ) : 295 ‚Äì 332 . Kerr , W . R . , J . Lerner , andA . Schoar . 2014 . ‚Äú TheConsequencesofEntrepreneurialFinance : EvidencefromAngelFinancings . ‚Äù ReviewofFinancial Studies 27 ( 1 ) : 20 ‚Äì 55 . Krishnan , V . , andS . Bhattacharya . 2002 . ‚Äú TechnologySelectionandCommitmentinNewProductDevelopment : TheRoleofUncertaintyand DesignFlexibility . ‚Äù ManagementScience 48 ( 3 ) : 313 ‚Äì 327 . Lanjouw , J . O . , andM . Schankerman . 2001 . ‚Äú CharacteristicsofPatentLitigation : AWindowonCompetition . ‚Äù RANDJournalofEconomics 32 ( 1 ) : 129 ‚Äì 151 . Lerner , J . 1994a . ‚Äú TheSyndicationofVentureCapitalInvestments . ‚Äù FinancialManagement 23 : 16 ‚Äì 27 . Lerner , J . 1994b . ‚Äú VentureCapitalistsandtheDecisiontoGoPublic . ‚Äù JournalofFinancialEconomics 35 : 293 ‚Äì 316 . Lerner , J . , H . Shane , andA . Tsai . 2003 . ‚Äú DoEquityFinancingCyclesMatter ? EvidencefromBiotechnologyAlliances . ‚Äù JournalofFinancialEco - nomics 67 ( 3 ) : 411 ‚Äì 446 . Levinthal , D . A . , andJ . G . March . 1993 . ‚Äú TheMyopiaofLearning . ‚Äù StrategicManagementJournal 14 : 95 ‚Äì 112 . Long , J . S . , andJ . Freese . 2003 . RegressionModelsforCategoricalDependentVariablesUsingSTATA . CollegeStation , TX : STATAPress . MacMillan , I . , E . Roberts , V . Livada , andA . Wang . 2008 . CorporateVentureCapital ( CVC ) : SeekingInnovationandStrategicGrowth . Gaithersburg , MD : NationalInstituteofStandardsandTechnology , U . S . DepartmentofCommerce . Mann , R . J . , andT . W . Sager . 2007 . ‚Äú Patents , VentureCapital , andSoftwareStart - Ups . ‚Äù ResearcherPolicy 36 : 193 ‚Äì 208 . Manski , C . F . , andD . L . McFadden . 1981 . StructuralAnalysisofDiscreteDataandEconometricApplications . Cambridge , MA : MITPress . Maula , M . V . J . , E . Autio , andG . C . Murray . 2009 . ‚Äú CorporateVentureCapitalandtheBalanceofRisksandRewardsforPortfolioCompanies . ‚Äù JournalBusinessVenturing 24 ( 3 ) : 274 ‚Äì 286 . Maula , M . V . J . , T . Keil , andS . A . Zahra . 2013 . ‚Äú TopManagement ‚Äô sAttentiontoDiscontinuousTechnologicalChange : CorporateVentureCapital asanAlertMechanism . ‚Äù OrganizationScience 24 ( 3 ) : 926 ‚Äì 947 . Megginson , W . L . , andK . A . Weiss . 1990 . ‚Äú VentureCapitalistCertificationinInitialPublicOfferings . ‚Äù JournalofFinance 46 ( 3 ) : 879 ‚Äì 903 . Miemietz , M . 2013 . CFAInstituteIndustryGuides : ThePharmaceuticalIndustry . Lexington , KY : CFAInstitute . NationalResearchCouncil . 2009 . VentureFundingandtheNIHSBIRProgram . Washington , DC : NationalAcademyPress . NationalVentureCapitalAssociation . 2010 . VCinvestments2010 . http : / / www . nvca . org / . Newsweek . 2017 . Trump ‚Äô sPlanforLoweringBigPharmaDrugPricesComesataHighCost . www . newsweek . com / trump - drug - prices - big - pharma - 552295 . Pahnke , E . C . , R . Katila , andK . M . Eisenhardt . 2015 . ‚Äú WhoTakesYoutotheDance ? HowFundingPartnersInfluenceInnovativeActivityin YoungFirms . ‚Äù AdministrativeScienceQuarterly 60 ( 4 ) : 596 ‚Äì 633 . Park , H . D . , andH . K . Steensma . 2011 . ‚Äú WhenDoesCorporateVentureCapitalAddValueforNewVentures ? ‚Äù StrategicManagementJournal 33 ( 1 ) : 1 ‚Äì 22 . Paul , S . M . , D . S . Mytelka , C . T . Dunwiddie , C . C . Persinger , B . H . Munos , S . R . Lindborg , andA . L . Schacht . 2010 . ‚Äú HowtoImproveR & DProductivity : ThePharmaceuticalIndustry ‚Äô sGrandChallenge . ‚Äù NatureReviewsDrugDiscovery 9 : 203 ‚Äì 213 . Perez , R . C . 1986 . InsideVentureCapital : Past , Present , andFuture . NewYork : Praege . Pharma . 2015 . 2015ProfileBiopharmaceuticalResearchIndustry . WashingtonD . C : Pharma . PricewaterhouseCoopers . 2014 . PricewaterhouseCoopers / NationalVentureCapitalAssociationMoneyTreeReport . Washington , D . C : Pricewater - houseCoopers . Prowse , S . 1998 . ‚Äú AngelInvestorsandtheMarketforAngelInvestments . ‚Äù JournalofBanking & Finance 22 : 785 ‚Äì 792 . Puri , M . , andR . Zarutskie . 2012 . ‚Äú OntheLifeCycleDynamicsofVenture - CapitalandNonventure - CapitalBackedCompanies . ‚Äù JournalofFi - nance 67 ( 6 ) : 2247 ‚Äì 2293 . Rothaermel , F . R . , andD . L . Deeds . 2004 . ‚Äú ExplorationandExploitationAlliancesinBiotechnology : ASystemofNewProductDevelopment . ‚Äù StrategicManagementJournal 25 ( 3 ) : 201 ‚Äì 221 . Sah , R . K . , andJ . E . Stiglitz . 1986 . ‚Äú TheArchitectureofEconomicSystems : HierarchiesandPolyarchies . ‚Äù TheAmericanEconomicReview 76 ( 4 ) : 716 ‚Äì 727 . Sahlman , W . 1990 . ‚Äú TheStructureandGovernanceofVentureCapitalOrganizations . ‚Äù JournalofFinancialEconomics 27 ( 2 ) : 473 ‚Äì 521 . Santos , F . M . , andK . M . Eisenhardt . 2009 . ‚Äú ConstructingMarketsandShapingBoundaries : EntrepreneurialAgencyinNascentFields . ‚Äù AcademyofManagementJournal 52 ( 4 ) : 643 ‚Äì 671 . Schilling , M . A . 2009 . ‚Äú UnderstandingtheAllianceData . ‚Äù StrategicManagementJournal 30 ( 3 ) : 233 ‚Äì 260 . Schwienbacher , A . 2013 . ‚Äú TheEntrepreneur ‚Äô sInvestorChoice : TheImpactonLater - StageFirmDevelopment . ‚Äù JournalBusinessVenturing 28 ( 4 ) : 528 ‚Äì 545 . Stuart , T . , H . Hoang , andC . Ralph . 1999 . ‚Äú InterorganizationalEndorsementsandthePerformanceofEntrepreneurialVentures . ‚Äù Administra - tiveScienceQuarterly 44 ( 2 ) : 315 ‚Äì 349 . Vanacker , T . , M . Meuleman , andS . Manigart . 2014 . ‚Äú Path - DependentEvolutionversusIntentionalManagementofInvestmentTiesin Science - BasedEntrepreneurialVentures . ‚Äù EntrepreneurshipTheory & Practice 38 ( 3 ) : 671 ‚Äì 690 . Wong , A . , M . Bhatia , andZ . Freeman . 2009 . ‚Äú AngelFinance : TheOtherVentureCapital . ‚Äù StrategicChange 18 ( 7 ‚Äì 8 ) : 221 ‚Äì 230 . Ziedonis , A . A . 2007 . ‚Äú RealOptionsinTechnologyLicensing . ‚Äù ManagementScience 53 ( 10 ) : 1618 ‚Äì 1633 . 19